Madrigal Pharmaceuticals
Manufacturing · Pennsylvania, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
200 Barr Harbor Dr Ste 200, Conshohocken...Phone Number
(267) 824-2827Website
www.madrigalpharma.comRevenue
$1.3 BillionStock Symbol
MDGLIndustry
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) -selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.Explore more
Madrigal Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Madrigal Pharmaceuticals
Compare insights from companies similar to Madrigal Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Madrigal Pharmaceuticals
$1.3B
501-1,000
Public
$562.4M
2011
RF
Ronald FilippoExecutive Vice President & Chief Information Officer
Madrigal Pharmaceuticals Tech Stack
A closer look at the technologies used by Madrigal Pharmaceuticals
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Madrigal Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) -se... Read More
